NIH launches search to find HIV drug that won’t cause heart conditions

A new study by the National Institutes of Health will explore the ways in which patients with HIV can avoid heart attacks, because one could be especially deadly for someone with the condition, reports the Baltimore Sun.

Cardiovascular disease is one of the most prevalent complications patients get after contracting HIV. To combat it, NIH has organized a long-term study to provide a drug that will treat HIV without causing heart problems. The research will take place at 100 hospitals, academic centers and health facilities around the world.

"When I first started taking care of patients in the 1980s they virtually would all die, but now they're living and getting complications from the disease, the most prominent of which is cardiovascular disease," said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

To read the full story, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.